Results 141 to 150 of about 214,719 (303)
Adeno-associated virus mediated expression of human erythropoietin in vitro
AIM: To investigate the expression of human erythropoietin (hEpo) in 293 cell line using adeno-associated virus (AAV) vector, and provide information for its potential application in human gene therapy.
Zhao, XC, Diao, Y, Wang, GJ, Xu, RA
core
LDLR-Gene therapy for familial hypercholesterolaemia: Problems, progress, and perspectives
Coronary artery diseases (CAD) inflict a heavy economical and social burden on most populations and contribute significantly to their morbidity and mortality rates.
Charles Coutelle +11 more
core +1 more source
The Dynamics of Neurofilament Light Chain in Spinal Muscular Atrophy
Objective Newborn screening (NBS) for spinal muscular atrophy (SMA) facilitates early diagnosis and treatment for affected individuals. However, fluid biomarkers that provide early insights into disease activity and outcomes in a neonatal cohort and those unable to access (due to reimbursement criteria) or deferring immediate treatment are lacking ...
Arlene D'Silva +13 more
wiley +1 more source
CRISPR/Cas9 has revolutionized the field of gene therapy, but delivery remains an outstanding issue. We propose a nonviral gold‐nanoparticle platform for co‐delivery of CRISPR/Cas9 ribonucleoprotein and long 2.1 kilobase dsDNA transgene constructs. This CRISPR‐AuNP is inexpensive to produce and mediate gene editing and DNA delivery in T cells and CD34+
Rachel A. Cunningham +8 more
wiley +1 more source
Xun Zhou,1,2,* Jingzhou Liu,2,* Shuang Xiao,2,3,* Xiaoqing Liang,1,2 Yi Li,2 Fengzhen Mo,3 Xin Xin,2 Yang Yang,2 Chunsheng Gao1,2 1School of Pharmacy, Henan University, Kaifeng, People’s Republic of China; 2State Key Laboratory of Toxicology ...
Liu J +8 more
core
Modified Adeno-associated virus (AAV) particles for gene therapy
The present invention relates to improved adeno-associated virus (AAV) particles for gene delivery and gene therapy. Provided are adeno associated virus (AAV) particles that comprise a modified capsid. The present invention further relates to methods for
Heppenstall, P. +3 more
core
Aim: To develop an assay format for detection of total anti-adeno–associated virus 2 (AAV2) antibodieswith low capsid material consumption. Methods: An immune complex (IC) assay format was developed.The format is based on the formation of ICs in solution
Kay Stubenrauch (10832767) +5 more
core +1 more source
Copyright information:Taken from "Adeno-associated virus (AAV)-mediated suppression of Ca2+/calmodulin kinase IV activity in the nucleus accumbens modulates emotional behaviour in mice"http://www.biomedcentral.com/1471-2202/8/105BMC Neuroscience 2007;8():
Hilmar Bading (78535) +4 more
core +1 more source
We developed an assay to distinguish cellular binding from internalization. Compatible with microscopy and high‐throughput screening, the method identifies ligand‐mediated uptake. Applying top candidates to a protein‐based DNA carrier enhanced transfection efficiency, providing a rational strategy to improve non‐viral gene delivery systems.
David Scherer +5 more
wiley +1 more source
Objective Myositis‐specific autoantibodies guide the diagnosis and classification of idiopathic inflammatory myopathies, but current immunoassays vary in accuracy, particularly for autoantibodies associated with interstitial lung disease. To compare the performance of the luciferase immunoprecipitation systems (LIPS) assay with line blot and ...
Peter D. Burbelo +14 more
wiley +1 more source

